Table 1 Associations between membranous and non-membranous PODXL expression with clinciopathological parameters in intestinal type and pancreatobiliary type tumours, respectively
Intestinal type | Pancreatobiliary type | |||||
|---|---|---|---|---|---|---|
PODXL NM | PODXL M | P | PODXL NM | PODXL M | P | |
(n = 51) | (n = 12) | (n = 52) | (n = 55) | |||
Age | ||||||
(median, range) | 66.0 (38.0–83.0) | 67.5 (44.0–74.0) | 0.972 | 66.0 (44.0–81.0) | 68.0 (44.0–81.0) | 0.613 |
Sex | ||||||
Women | 28 (82.4) | 6 (17.6) | 0.761 | 17 (34.0) | 33 (66.0) | 0.005 |
Men | 23 (79.3) | 6 (20.7) | 35 (61.4) | 22 (38.6) | ||
Tumour origin | ||||||
Duodenum | 12 (85.7) | 2 (14.3) | 0.610 | |||
Ampulla intestinal type | 39 (79.6) | 10 (20.4) | ||||
Ampulla pancreatobiliary type | 14 (73.7) | 5 (26.3) | 0.005 | |||
Distal bile duct | 23 (51.1) | 22 (48.9) | ||||
Pancreas | 15 (34.9) | 28 (65.1) | ||||
Tumour size mm | ||||||
(median, range) | 30.0 (5.0–90.0) | 26.5 (12.0–40.0) | 0.923 | 30.0 (5.0–70.0) | 30.0 (15.0–70.0) | 0.313 |
Differentiation grade | ||||||
Well-moderate | 26 (83.9) | 5 (16.1) | 0.565 | 24 (61.5) | 15 (38.5) | 0.044 |
Poor | 25 (78.1) | 7 (21.9) | 28 (41.2) | 40 (58.8) | ||
T-stage | ||||||
T1 | 4 (100.0) | 0 (0.0) | 0.246 | 2 (100.0) | 0 (0.0) | 0.392 |
T2 | 9 (81.8) | 2 (18.2) | 4 (40.0) | 6 (60.0) | ||
T3 | 21 (84.0) | 4 (16.0) | 34 (43.6) | 44 (56.4) | ||
T4 | 17 (73.9) | 6 (26.1) | 12 (70.6) | 5 (29.4) | ||
N-stage | ||||||
N0 | 28 (84.8) | 5 (5.2) | 0.936 | 17 (56.7) | 13 (43.3) | 0.315 |
N1 | 13 (68.4) | 6 (31.6) | 21 (46.7) | 24 (53.3) | ||
N2 | 10 (90.9) | 1 (9.1) | 14 (43.8) | 18 (56.2) | ||
Margins | ||||||
R0 | 15 (88.2) | 2 (11.8) | 0.375 | 3 (50.0) | 3 (50.0) | 0.944 |
R1-Rx | 36 (78.3) | 10 (21.7) | 49 (48.5) | 52 (51.5) | ||
Perineural growth | ||||||
No | 38 (86.4) | 6 (13.6) | 0.099 | 14 (63.6) | 8 (36.4) | 0.115 |
Yes | 13 (68.4) | 6 (31.6) | 38 (44.7) | 47 (55.3) | ||
Invasion of lymphatic vessels | ||||||
No | 26 (89.7) | 3 (10.3) | 0.107 | 16 (50.0) | 16 (50.0) | 0.850 |
Yes | 25 (73.5) | 9 (26.5) | 36 (48.0) | 39 (52.0) | ||
Invasion of blood vessels | ||||||
No | 48 (82.8) | 10 (17.2) | 0.217 | 35 (50.0) | 35 (50.0) | 0.691 |
Yes | 3 (60.0) | 2 (40.0) | 17 (45.9) | 20 (54.1) | ||
Growth in peripancreatic fat | ||||||
No | 35 (85.4) | 6 (14.6) | 0.227 | 13 (59.1) | 9 (40.9) | 0.271 |
Yes | 16 (72.7) | 6 (27.3) | 39 (45.9) | 46 (54.1) | ||
Adjuvant chemotherapy | ||||||
None | 40 (88.9) | 5 (11.1) | 0.145 | 23 (46.0) | 27 (54.0) | 0.348 |
5-FU-analogue | 2 (40.0) | 3 (60.0) | 5 (62.5) | 3 (37.5) | ||
Gemcitabine | 4 (57.1) | 3 (42.9) | 20 (45.5) | 24 (54.5) | ||
Gemcitabine + capecitabine | 1 (100.0) | 0 (0.0) | 1 (50.0) | 1 (50.0) | ||
Oxaliplatin + 5-FU analogue | 4 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | ||
Gemcitabine + oxaliplatin | 0 (0.0) | 1 (100.0) | 2 (100.0) | 0 (0.0) | ||